Somewhat Favorable Press Coverage Somewhat Unlikely to Affect IRIDEX Corporation (IRIX) Stock Price
News articles about IRIDEX Corporation (NASDAQ:IRIX) have trended somewhat positive recently, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. IRIDEX Corporation earned a coverage optimism score of 0.25 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 46.3478047426132 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Iridex : working on smart waste management projects with Telekom (4-traders.com)
- ETFs with exposure to IRIDEX Corp. : October 27, 2017 (finance.yahoo.com)
- IRIDEX to Present at Upcoming Investor Conferences (finance.yahoo.com)
- IRIDEX Corporation (IRIX) Scheduled to Post Earnings on Thursday (americanbankingnews.com)
IRIDEX Corporation (NASDAQ IRIX) traded up 0.47% during trading on Tuesday, reaching $8.50. The company had a trading volume of 9,294 shares. The stock’s market cap is $98.32 million. IRIDEX Corporation has a 52-week low of $7.58 and a 52-week high of $16.39. The company has a 50-day moving average price of $9.44 and a 200 day moving average price of $9.37.
IRIDEX Corporation (NASDAQ:IRIX) last released its earnings results on Thursday, August 3rd. The medical equipment provider reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.06). The business had revenue of $10.00 million during the quarter, compared to analysts’ expectations of $10.48 million. IRIDEX Corporation had a negative net margin of 37.62% and a negative return on equity of 16.87%. On average, analysts anticipate that IRIDEX Corporation will post ($0.72) earnings per share for the current year.
Separately, Zacks Investment Research raised IRIDEX Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect IRIDEX Corporation (IRIX) Stock Price” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://theolympiareport.com/2017/10/31/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-iridex-corporation-irix-stock-price.html.
About IRIDEX Corporation
IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD).
Receive News & Ratings for IRIDEX Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.